<DOC>
	<DOCNO>NCT02437604</DOCNO>
	<brief_summary>Each patient participate study approximately 7 week . Participation include screen period 21 day 4 treatment period ; consist 3-day/2-night inpatient period .</brief_summary>
	<brief_title>Study Determine Pharmacokinetics Tolerability Fluticasone Propionate MDPI Fluticasone Propionate/Salmeterol MDPI Compared High Strength FLOVENT® DISKUS® ADVAIR® DISKUS® Patients With Persistent Asthma 12 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Criteria : • The patient persistent asthma . To meet current asthma therapy requirement patient must currently treat inhaled corticosteroid ( ICSs ) dose stable least 30 day SV . Written inform consent/assent obtain . For adult patient ( age 18 year old , applicable per local regulation ) , write ICF must sign dated patient conduct studyrelated procedure . For minor patient ( age 12 17 year , applicable per local regulation ) , write ICF must sign dated parent/legal guardian write assent form must sign dated patient ( applicable ) conduct study related procedure . Note : Age requirement specify local regulation . The patient male female 12 year age old , visit ICF/assent form sign ( SV ) . Asthma diagnosis : The patient diagnosis asthma define NIH . The asthma diagnosis present minimum 3 month stable ( defined exacerbation change asthma medication ) least 30 day provide informed consent . The patient able demonstrate acceptable reproducible inhalation technique DISKUS device Teva MDPI device . The patient able withhold ( judged investigator ) rescue medication least 6 hour SV treatment visit spirometry perform . The patient body mass index ( BMI = weight [ kg ] ÷ height2 [ ] ) within 5th 97thpercentiles patient 's age gender . The patient must weight 115 pound higher . The patient/parent/legal guardian/caregiver capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent/assent compliant study requirement ( eg , dose schedule , visit schedule , blood draw , procedure , record keep ) . Other criterion may apply , please contact investigator information . The patient history lifethreatening asthma exacerbation define protocol asthma episode require intubation and/or associate hypercapnia , respiratory arrest , hypoxic seizure . The patient pregnant lactating , plan become pregnant study period 30 day patient 's last studyrelated visit ( eligible patient , applicable ) . Eligible female patient unwilling employ appropriate contraceptive measure ensure pregnancy occur study exclude . Any patient become pregnant study withdrawn study . The patient participate randomized patient investigational drug study within 30 day ( start final followup visit study ) precede SV plan participate another investigational drug study time study . The patient previously participate Fp MDPI FS MDPI study . Participation define randomization treatment . The patient know hypersensitivity corticosteroid , salmeterol , excipients study drug ( ie , lactose ) . The patient treat known cytochrome P450 ( CYP ) 3A4 inhibitor ( eg , azole antifungal , ritonavir , clarithromycin ) within 30 day SV plan treat CYP3A4 inhibitor study.The patient treat prohibited medication prescribe ( per protocol ) washout period SV . The patient either lose donated ≥500 mL whole blood within 60 day first dose study drug patient receive donated plasma , white blood cell , platelet within 14 day first dose study drug . Patients plan donate blood blood product study within 90 day completion study also exclude . The patient currently smoke smoke history 10 pack year ( pack year define smoke 1 pack cigarettes/day 1 year ) . The patient may use tobacco product within past year ( eg , cigarette , cigar , chew tobacco , pipe tobacco ) . The patient culturedocumented suspected bacterial viral upper respiratory tract infection ( URTI ) low respiratory tract infection ( LRTI ) , The patient history alcohol drug abuse within 2 year precede SV . The patient asthma exacerbation require systemic corticosteroid within 30 day SV , hospitalization asthma within 2 month SV . The patient untreated oral candidiasis SV . Patients clinical visual evidence oral candidiasis agree receive treatment comply appropriate medical monitoring may enter study . Note : Azole antifungal prohibit . The patient either employee immediate relative employee investigational center . A member patient 's household participate study time . However , enrol patient completes discontinues participation study , another patient household may screen . The patient disease/condition medical judgment investigator would put safety patient risk participation could affect efficacy safety analysis disease/condition worsen study . Other criterion may apply , please contact investigator information .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>